Remission of generalized anxiety disorder after 6 months of open-label treatment with Venlafaxine XR

Psychotherapy and Psychosomatics

Volumn 82, Issue 6, 2013, Pages 363-371

  Rickels, Karl ^a   Etemad, Bijan ^a   Rynn, Moira A ^c   Lohoff, Falk W ^a   Mandos, Laura A ^b   Gallop, Robert ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c Columbia University ^*  (United States)

Author keywords

Adverse events; Generalized anxiety disorder; Long term treatment; Remission; Venlafaxine XR

Indexed keywords

VENLAFAXINE;

ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DROWSINESS; EYSENCK NEUROTICISM SCORE; EYSENCK PERSONALITY QUESTIONNAIRE; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MYALGIA; NAUSEA; NERVOUSNESS; NIGHT SWEAT; ORGASM; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA; ASSESSMENT OF HUMANS; DEPRESSION; OPEN STUDY; ORGASM DISORDER;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; TIME FACTORS;

EID: 84886304723     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000351410     Document Type: Article

References (36)

1. Ballenger JC: Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60(suppl 22): 29-34.
2. Rickels K, Rynn M, Iyengar M, Duff D: Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67: 41-47.
3. Pollack HM, Meoni P, Otto WM, Hackett D: Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharm 2003; 23: 250-259.
4. Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495-505.
5. Rickels K, Etemad B, Khalid-Khan S, Lohoff FW, Rynn MA, Gallop RJ: Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry 2010; 67: 1274-1281.
6. Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, Fisher S, Frankenthaler LM: Imipramine and chlordiazepoxide in depressive and anxiety disorders. 2. Efficacy in anxious outpatients. Arch Gen Psychiatry 1986; 43: 79-85.
7. Rickels K, Downing R, Schweizer E, Hassman H: Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993; 50: 884-895.
8. First MB, Spitzer RL, Gibbon M, Williams JB: Structured clinical Interview for Axis I DSM-IV Disorders (version 2.0). New York, New York State Psychiatric Institute, 1996.
9. Hamilton MA: the assessment of anxiety status by rating. Br J Med Psychol 1959; 32: 50-55.
10. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Revised. Rockville, National Institute of Mental Health, 1976.
11. Hamilton MA: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
12. Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
13. Sheehan DV, Harnett-Sheehan K, Raj BA: The measurement of disability. Int Clin Psychopharmacol 1996; 11(suppl 3):89-95.
14. Meyer TJ, Miller ML, Metzger RL, Borkovec TD: Development and validation of the Penn State worry questionnaire. Behav Res Ther 1990; 28: 487-495.
15. Bech P: Rating Scales for Psychopathology, Health Status and Quality of Life. New York, Springer, 1993, pp 402-404.
16. Eysenck HJ: Manual of the Maudsley Personality Inventory. London, University of London Press, 1959.
17. Kraemer HC, Bloch DA: Kappa coefficients in epidemiology: an appraisal of a reappraisal. J Clin Epidemiol 1988; 41: 959-968.
18. Zweig MH, Campbell G: Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
19. Porock D, Parker-Oliver D, Petroski GF, Rantz M: The MDS mortality risk index: the evolution of a method for predicting 6-month mortality in nursing home residents. BMS Res Notes 2010; 3: 1-8.
20. Altman DG, Andersen PK: Bootstrap investigation of the stability of a Cox regression model. Stat Med 1989; 8: 771-783.
21. Sauerbrei W: The use of re-sampling methods to simplify regression models in medical statistics. Appl Statist 1999; 48: 313-329.
22. Moret C, Isaac M, Briley M: Review: problems associated with long-term treatment with selective serotonin reuptake inhibitors. J Psychopharmacol 2009; 23: 967-974.
23. Shea MT, Pilkonis PA, Beckham E, Collins JF, Elkin I, Sotsky SM, Docherty JP: Personality disorders and treatment outcome in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1990; 147: 711-718.
24. Joffee RT, Regan JJ: Personality and response to tricyclic antidepressants in depressed patients. J Nerv Ment Dis 1989; 177: 745-749.
25. Diguer L, Barber JP, Luborsky L: Three concomitants: personality disorders, psychiatric severity, and outcome of dynamic psychotherapy of major depression. Am J Psychiatry 1993; 150: 1246-1248.
26. Rickels K, Downing RW, Case GW, Csanalosi I, Chung H, Winokur A, Gingrich R: Sixweek trial with diazepam: some clinical observations. J Clin Psychiatry 1985; 46: 470-474.
27. Stein MK, Downing RW, Rickels K: The Minnesota multiphase personality inventory in predicting response to pharmacotherapy of neurotic outpatients. J Nerv Ment Dis 1979; 167: 542-547.
28. Massion AO, Dyck IR, Shea MT, Phillips KA, Warsaw MG, Keller MB: Personality disorders and time to remission in generalized anxiety disorder, social phobia, and panic disorder. Arch Gen Psychiatry 2002; 59: 434-440.
29. Rickels K, Schweizer E, Case GW, Garcia-Espana F: Benzodiazepine dependence, withdrawal severity, and clinical outcome: effects of personality. Psychopharmacol Bull 1988; 24: 415-420.
30. Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F: The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998; 28: 713-720.
31. Cuijpers P, Smit F, Penninx BW, de Graaf R, ten Have M, Beekman AT: Economic costs of neuroticism. Arch Gen Psychiatry 2010; 67: 1086-1093.
32. Rickels K (ed): Non-Specific Factors in Drug Therapy. Springfield, Thomas, 1968.
33. Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H: Long term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988; 45: 444-450.
34. Fava GA: Statistical alchemy for drug treatment of generalized anxiety disorder: a commentary on the meta-analysis by Baldwin et al. (BMJ 2011; 342:d1199). Psychother Psychosom 2011; 80: 261-263.
35. Berney P, Halperin D, Tango R, Daenicker- Dayer I, Schulz P: A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorder. Psychopharmacol Bull 2008; 41: 39-47.
36. Fava GA, Offidani E: The mechanism of tolerance in antidepressant action. Prog Neuropsuchopharmacol Biol Psychiatry 2011; 35: 1593-1602.